Exchange: NASDAQ·Updated 04:48 AM EDT
ALNY logo

ALNYAlnylam Pharmaceuticals Inc

$312.20
$0.59
(0.19%)
Pre-Market
Prev Close $312.79
EarningsJul 30
Mkt Cap$43.19B
Vol218.00
News
all
press releases
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’
AstraZeneca and Ionis announced on Thursday that their late-stage CARDIO-TTRansform trial for eplontersen (Wainua) failed to meet its main goal.
Stocktwits
News Placeholder
More News
News Placeholder
Nasdaq 100 Movers: PEP, ALNY
In early trading on Thursday, shares of Alnylam Pharmaceuticals topped the list of the day's best performing components of the Nasdaq 100 index, trading up 15.4%. Year to date, Alnylam Pharmaceuticals has lost about 6.1% of its value. And the worst performing Nasdaq 100 compon...
Nasdaq News: Markets
News Placeholder
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.
Zacks
News Placeholder
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stockread more...
Benzinga
News Placeholder
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
Zacks
News Placeholder
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.
Zacks
News Placeholder
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 10 years by 3.79% on an annualized basis producing an average annual return of 17.65%. Currently, Alnylam Pharmaceuticals has a marketread more...
Benzinga
News Placeholder
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.
Zacks
News Placeholder
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.
Zacks
<
1
2
...
>

Advertisement|Remove ads.